Vericel Corporation
VCELVericel Corporation (VCEL) is a biotechnology company specializing in the development and commercialization of autologous cell therapy products for the treatment of sports-related injuries, including cartilage and tendon repair. The company focuses on regenerative medicine technologies aimed at improving patient outcomes in musculoskeletal conditions.
Company News
The global stem cell therapy market is projected to grow from USD 21.9 billion in 2025 to USD 58.5 billion by 2034, driven by technological advancements, favorable regulations, and rising demand for regenerative medicine treatments for chronic diseases. North America leads the market with 48.87% share, while Asia-Pacific emerges as a key growth e...
Vericel Corporation announced preliminary 2025 financial results with total revenue of $276 million, driven by MACI revenue of $239.5 million. The company achieved 23% fourth quarter revenue growth, 74% gross margin, and 26% adjusted EBITDA margin, with GAAP net income profitability for the second consecutive year. The company completed its MACI ...
Baltimore-based Brown Capital Management sold 861,020 shares of Vericel Corporation for approximately $31 million in Q3 2025, reducing its stake while the biotech company reported strong quarterly revenue growth of 17%.
MediWound reported a 43% quarterly revenue increase to $5.7 million, improved gross margins, and advanced its Phase III EscharEx trial while establishing strategic partnerships with wound care leaders.
Vericel reported Q2 2025 revenue growth of 20% to $63.2 million, driven by strong MACI cartilage repair franchise performance. The company expanded gross margins to 74% and narrowed net loss per share, while preparing for potential market expansion into ankle cartilage repair.
